Global spending on medicines will reach $1.4 trillion in 2020, driven by increased healthcare access in emerging markets and high-priced new drugs for cancer and other diseases, according to a forecast by IMS Health released on Wednesday. That is up from about $1.07 trillion this year, representing a compound annual growth rate of 4 to 7 percent over the next five years, the "Global Medicines Use in 2020" report compiled by IMS Institute for Healthcare Informatics found. Some 225 new drugs will
NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the next decade. ii. China’s health challenges include significantly high rates of smoking, high pollution levels, and a rapidly aging population. iii. Given China’s healthcare challenges, Canadian healthcare developers should target cancer treatment, heart disease treatment, and age related solutions. iv. The cit
South Korean biotech Genexine Inc. licensed out three of its compounds for $100 million to a Chinese drug developer, exploring the Asian market for next-generation long-acting growth hormone treatments. Clinical-stage Genexine (KOSDAQ:095700) signed a licensing and technology transfer agreement with China's Tasgen, a subsidiary of Tasly Pharmaceutical Group Co. Ltd. (SH:600535). Under the deal reached this week, Genexine will grant the China rights for three compounds, GX-H9, GX-G6 and GX-G3, to Tasgen i
BGI, a Shenzhen genomics company, is edging closer to an IPO. The company now expects to raise $250 million on Shenzhen's Chi-Next Exchange sometime in July, following all-but-fin...
Naturally Splendid is a multifaceted biotechnology company that is developing, producing, commerc...
CohBar is an innovator and leader in the research and development of mitochondria-based therapeut...
Diamedica Inc is a development stage biopharmaceutical company. The Company is engaged in the dis...
Gilber Chan, the President of NAI500, presents the latest speech of 2016 investment strategy on Global Chinese Financial Forum - Vancouver Conference 2016: The Top 10 Developments...
China's policymakers still have ammunition to counter the mainland's slowing economy, including supply-side reforms and subsidized housing, HSBC said. In a note released Tu...
Consumer staples and services, health care, software and auto stocks are Henderson Global Investors' top Chinese stock picks for 2016 — but don't get your hopes up for a...
The leaders of the world's largest economies stuck to a goal of lifting their collective output by an extra 2 percent by 2018, even though growth remains uneven and weaker than expect...
The renminbi's status as a global reserve currency may be effectively guaranteed following formal backing by International Monetary Fund (IMF) staff, according to economists, but trad...
Lexaria Bioscience Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company” or “Lexaria”) announces the filing of a new provisional patent application and stock and o...
, a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 ...
today closed its previously-announced offering, issuing a total of $10 million of its equity units. Eastern Capital Limited ("Eastern") and Shenzhen Hepalink Pharma...
|Company Name||Symbol||Price||Change||Vol(k)||Day's Range||Contact|
|1||AVEO Pharmaceuticals Inc||NASDAQ:AVEO||1.250||
||54841423||1.05 - 1.38|
|2||Kane Biotech Inc.||TSXV:KNE||0.125||
||58000||0.115 - 0.125|
|3||Oragenics Inc||NYSE MKT:OGEN||0.416||
||31267||0.3780 - 0.4583|
|4||Retractable Technologies Inc||NYSE MKT:RVP||1.150||
||83868||1.07 - 1.15|
|5||Sunesis Pharmaceuticals Inc||NASDAQ:SNSS||3.190||
||2103917||2.85 - 3.20|
|6||MEI Pharma Inc||NASDAQ:MEIP||2.300||
||635908||2.14 - 2.30|
|7||Apricus Biosciences Inc||NASDAQ:APRI||1.160||
||1981895||1.08 - 1.27|
||38813||1.81 - 1.93|
||125087||4.42 - 4.89|
|11||Esperion Therapeutics Inc||NASDAQ:ESPR||44.340||
||764853||41.42 - 44.54|
|12||Enzo Biochem Inc||NYSE:ENZ||11.540||
||723722||10.85 - 11.61|
|13||Rexahn Pharmaceuticals Inc||NYSE MKT:RNN||3.150||
||235829||2.99 - 3.17|
|14||Centric Health Corp||TSX:CHH||0.730||
||278200||0.70 - 0.74|
|15||Pernix Therapeutics Holdings Inc||NASDAQ:PTX||4.620||
||184124||4.37 - 4.69|